QNRX (Quoin Pharmaceuticals Ltd.) Dana dhuwit perusahaan

Quoin Pharmaceuticals - logo grafis emiten QNRX

The market for rare skin pathology therapies remains largely untapped, guaranteeing Quoin Pharmaceuticals (QNRX) exclusive access to patients. Investments in small molecule clinical trials provide high potential, while a strong team of biochemists ensures the quality of development. The company's cash position demonstrates current liquidity, with the latest value recorded as 0.03, which determines the business's resilience to crises.

QNRX - Sisa dhuwit perusahaan Quoin Pharmaceuticals ing rentang 04.07.2022 - 21.11.2026

Rincian metrik keuangan lan pasar quoinpharma.com (QNRX)

- indikator valuasi pasar bisnis:
Analisis fundamental perusahaan:Quoin Pharmaceuticals Ltd
Produk mawa merek Quoin Pharmaceuticals

For Quoin Pharmaceuticals (QNRX), which operates within the strict FDA regulatory framework for orphan drugs, the volume of liquid reserves determines the ability to maintain patent protection. This metric aggregates all cash and cash equivalents at the close of the trading day. By analyzing the organization's cash balances, an investor assesses the margin of safety for completing clinical trials. While a high level of liquidity minimizes default risk, it may indicate inefficient capital allocation. This balance sheet confirms the financial stability of the business.